Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.
(Sharecast News) - Haleon reported a 3.4% rise in organic revenue for the third quarter on Thursday, supported by strong demand in its oral health and vitamins, minerals and supplements (VMS) categories, and solid performance in emerging markets.
Reported revenue rose 0.7% to £2.8bn.
Growth was led by a 6.9% organic increase in oral health sales to £867m, reflecting robust innovation and continued market share gains for Sensodyne and parodontax.
VMS revenue rose 5.9% to £422m, buoyed by strong demand for Centrum and Emergen-C, while pain relief grew 3.7% to £647m.
Respiratory health, which had benefited from last year's strong cold and flu season, fell 1.8% on an organic basis and 12.2% reported.
Regionally and on an organic basis, EMEA and Latin America delivered 5.3% organic growth, Asia-Pacific rose 5.1%, and North America edged 0.4% higher, with consumption said to be running ahead of the wider market.
Revenue in emerging markets increased 7.1%, driven by double-digit growth in India and mid-single-digit gains in China.
"We delivered a good performance in the third quarter," said chief executive Brian McNamara.
"All regions delivered positive organic revenue growth, driven by strong in-market execution and the continued roll-out of our innovation pipeline.
"EMEA and LatAm performed well, and we continued to grow market share in North America despite a challenging consumer environment."
He added that oral Health was "the standout performer", with innovation driving strong market share gains for Sensodyne and Parodontax.
"VMS also delivered a good performance, supported by new launches for Centrum, Emergen-C, and Caltrate.
"We continue to deliver against our capital allocation priorities and so far this year have returned £1.1bn to shareholders."
Haleon said it was on track to meet its full-year guidance, expecting organic revenue growth of around 3.5% and high single-digit organic operating profit growth, assuming a normal cold and flu season.
It reiterated its disciplined approach to capital allocation, having completed a £500m share buyback and paid around £600m in dividends year to date.
The FTSE 100 consumer health company also flagged a foreign exchange translation headwind of about 3.3% on revenue and 5.1% on adjusted operating profit for 2025, saying it expected the net impact of recent disposals, including ChapStick and non-US nicotine replacement therapy assets, to dilute full-year revenue by roughly 2%.
At 0908 GMT, shares in Haleon were up 1.91% at 351.5p.
Reporting by Josh White for Sharecast.com.
